4.0: CR/CRh 44% vs 23.1% in NPM1m, 40% vs 24.5% in KMT2Ar
3.1: 2 approved rivals in NPM1m and 1 in KMT2Ar
3.0: ~60% of R/R patients still menin-naive
3.0: ~$450M menin class sales in R/R AML in 2029
3.0: registration-directed Phase 2 with data in both genotypes
3.3 of 5: pursue with conditions